Battaglia Parodi, Maurizio Di Bartolo, Emanuele Brue, Claudia Cappello, Ezio Furino, Claudio Giuffrida, Sebastiano Imparato, Manuela Reibaldi, Michele
Published in
European journal of ophthalmology
To evaluate the efficacy and the rate of side effects of the pegylated aptamer pegaptanib in the treatment of patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and a history of previous arterial thromboembolic events (ATEs). Twenty-three eyes of 23 patients with subfoveal CNV due to AMD and cerebro...
Thalgott, V. Feucht, N. Lohmann, C. P. Maier, M.
Published in
Der Ophthalmologe
HintergrundStandardtherapie der neovaskulären altersabhängigen Makuladegeneration (nAMD) ist die intravitreale Therapie mit „anti-vascular endothelial growth factor“ (VEGF). Nach den Ergebnissen der CATT (Comparison of Age-related Macular Degeneration Treatments Trials)-Studie bezüglich eines möglichen Zusammenhanges der intravitrealen Ranibizumab-...
Mikačić, Ivana Bosnar, Damir
Published in
Drug Safety
IntroductionIntravitreal bevacizumab (IVTB) is used to treat age-related macular degeneration (ARMD), although its use is off-label and its cardiovascular safety has not been unequivocally established.ObjectivesOur objective was to assess the cardiovascular safety of IVTB in patients with ARMD.MethodsWe conducted a systematic review and meta-analys...
Vaziri, Kamyar Fortun, Jorge A.
Published in
Current Ophthalmology Reports
Diabetic macular edema (DME), an ocular complication of diabetes mellitus, can potentially lead to devastating visual outcomes. Traditionally, laser photocoagulation has been the gold standard in the management of this condition. Over the recent years, however, several landmark clinical trials have shown beneficial effects of anti-VEGF agents over ...
Benedetto, Gregory Vestal, C. Greer Richardson, Christine
Published in
Targeted Oncology
Conventional delivery of chemotherapeutic agents leads to multiple systemic side effects and toxicity, limiting the doses that can be used. The development of targeted therapies to selectively deliver anti-cancer agents to tumor cells without damaging neighboring unaffected cells would lead to higher effective local doses and improved response rate...
Mattice, Christopher M. C. DeRosa, Maria C.
Published in
BioDrugs
The unique properties of nucleic acid aptamers and their suitability to therapeutic applications have attracted the attention of researchers for more than 2 decades. Aptamers exhibit significant advantages relative to antibody-based therapeutics and can serve dual roles as either the therapeutic agent itself or a targeting modality. Despite this in...
Biagi, C. Conti, V. Montanaro, N. Melis, M. Buccellato, E. Donati, M. Covezzoli, A. Amato, R. Pazzi, L. Venegoni, M.
...
Published in
European Journal of Clinical Pharmacology
PurposeThe purpose of this study is to conduct a comparative analysis of the suspected adverse drug reactions (ADRs) associated with intravitreal bevacizumab, ranibizumab and pegaptanib in the WHO database in order to have a real-life information on these drugs, which now is only based on data coming from clinical trials.MethodsADR reports for intr...
Stewart, Michael W.
Published in
Current Diabetes Reports
Vascular endothelial growth factor (VEGF) plays a pivotal role in the development of diabetic macular edema (DME), the leading cause of vision loss among working-aged individuals. A decade of clinical trials demonstrated that drugs that bind soluble VEGF restore the integrity of the blood-retinal barrier, resolve macular edema, and improve vision i...
Lipp, Melanie Bucher, Franziska Parthasarathy, Anand Hos, Deniz Onderka, Jasmine Cursiefen, Claus Bock, Felix
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology
BackgroundThe VEGF-A family plays a crucial role in the induction of pathological corneal neovascularization. The role of the different VEGF-A isoforms during lymphangiogenesis is only little-known. Current anti-angiogenic therapies in the eye and other organs inhibit all VEGF-A isoforms, and have effects on both blood and lymphatic vessels. Here w...
Krohne, T.U. Holz, F.G. Meyer, C.H.
Published in
Der Ophthalmologe
HintergrundNeben der topischen, periokulären und systemischen Gabe hat sich die intravitreale Injektion in den letzten Jahren als weiteres Standardverfahren der Medikamentenapplikation in der Augenheilkunde etabliert, insbesondere für die Therapie von Netzhauterkrankungen mit Substanzen zur Hemmung des gefäßendothelialen Wachstumsfaktors („vascular...
